FDA fast tracks BM-3103 gel for epidermolysis bullosa simplex

The FDA has granted Fast Track designation to BM-3103, a topical investigational product formulated as TolaSure Gel, for epidermolysis bullosa simplex (EBS), according to a June 23 announcement from BioMendics. The designation adds to the product’s previously granted Orphan Drug and Rare Pediatric Disease designations as the company advances a phase 2 study in patients with EBS.¹

“This designation is a significant milestone for BioMendics and, more importantly, for the individuals and families living with Epidermolysis Bullosa Simplex,” Karen McGuire, PhD, CEO of BioMendics, said in the announcement. “Combined with our Orphan Drug and Rare Pediatric Disease designations, Fast Track positions BM-3103 for an accelerated development path.”¹

Fast Track designation is a regulatory mechanism intended for drugs that treat serious conditions and address unmet medical need. It can allow more frequent FDA communication, opportunities for rolling review, and potential eligibility for priority review if relevant criteria are met, but it does not indicate that efficacy or safety has been established.²

BioMendics is evaluating BM-3103 in the TAMES-02 phase 2 trial, registered as NCT07027345, in collaboration with investigators at Northwestern University Feinberg School of Medicine and Stanford University School of Medicine. The company did not report trial design details, enrollment targets, dosing schedule, primary end point, efficacy results, or adverse event findings in the announcement.¹

EBS is one of the major inherited epidermolysis bullosa subtypes and is characterized by mechanical fragility of the skin, with blistering that often occurs after minor friction or trauma. Classification of epidermolysis bullosa has evolved as molecular diagnostics have improved, with EBS generally reflecting intraepidermal cleavage and, in many cases, pathogenic variants affecting keratinocyte structural proteins.³,⁴ Clinical severity varies widely, from localized blistering to more generalized disease with pain, pruritus, infection risk, nail involvement, impaired mobility, and quality-of-life effects.

Amy S. Paller, MD, MS, emphasized the patient-centered outcomes that matter in this disorder. “For individuals living with EBS, even modest improvements in blister burden, pain, itch, and quality of life can be meaningful,” she said. “The TAMES-02 study represents an important opportunity to further evaluate a potential therapeutic option for this patient population.”¹

Current management of EBS remains largely supportive and preventive. Care commonly includes avoidance of trauma and overheating, blister care, wound dressings, pain and itch management, treatment of secondary infection when present, nutritional support when needed, and multidisciplinary follow-up for more severe disease. No efficacy or safety data for BM-3103 were included in the FDA designation announcement, and the mechanism of action of BM-3103 was not described in the press release.¹

The broader epidermolysis bullosa therapeutic landscape has begun to shift with molecularly targeted and wound-directed approaches. However, available approved therapies have not eliminated the need for disease-specific options across EB subtypes. Regulatory designations such as orphan drug and rare pediatric disease status may provide incentives for development in rare conditions, while Fast Track status can streamline interactions with the FDA during clinical development. However, these designations are procedural and do not substitute for controlled evidence demonstrating clinical benefit.

For pediatric dermatologists and other clinicians caring for children with inherited blistering disorders, the main near-term implication is that BM-3103 remains investigational and is being studied in a phase 2 setting. The clinical relevance of the program will depend on whether TAMES-02 can demonstrate improvements in outcomes that are meaningful to patients and families, such as blister burden, pain, itch, wound healing, daily function, and quality of life, while maintaining an acceptable safety profile.

References

1. BioMendics receives FDA Fast Track designation for BM-3103 (TolaSure Gel) for epidermolysis bullosa simplex. BusinessWire. Published June 23, 2026. https://www.businesswire.com/news/home/20260623529098/en/BioMendics-Receives-FDA-Fast-Track-Designation-for-BM-3103-TolaSure-Gel-for-Epidermolysis-Bullosa-Simplex

2. US Food and Drug Administration. Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review. US Food and Drug Administration.

3. Fine JD, Bruckner-Tuderman L, Eady RAJ, et al. Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. J Am Acad Dermatol. 2014;70(6):1103-1126. doi:10.1016/j.jaad.2014.01.903

4. Has C, Bauer JW, Bodemer C, et al. Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. Br J Dermatol. 2020;183(4):614-627. doi:10.1111/bjd.18921